Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0427
Trial ID NCT03484702
Disease B-Cell Non-Hodgkin's Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017
Location approved US, Japan, EU, Switzerland, UK, Canada
Generation2nd
PhasePhase2
Recruitment statusCompleted
TitleTrial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
Year2018
CountryUnited States
Company sponsorCelgene
Other ID(s)JCAR017-BCM-001|U1111-1209-4055|2017-000106-38
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneanti‐CD19 single‐chain variable fragment; 4‐1BB costimulatory motif; CD3ζ T‐cell activation domain

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 1E8 cells
Donor type Autologous
Pts 10
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 50%(CR); 20%(PR); 0(SD); 30%(PD); 70%(ORR).The median duration of response was 9.1 months (95% confidence interval [CI], 2.1—not reached), and overall survival was 14.7 months (95% CI, 1.7—not reached).
Adverse reactions 50%(CRS), no grade ≥3 CRS events
References PMID: 35619325

Relationship Graph

Overview of Knowledge Graph